SWOT Analysis for Eris Lifesciences Ltd.

30 Day SMA crossing over 200 Day SMA, and current price greater than open
Companies with 10% increase in share price over three months, with rising net profit growth
Strong Momentum: Price above short, medium and long term moving averages
Consistent Highest Return Stocks over Five Years
Expensive Rockets (DVM)
Relative Outperformance versus Industry over 1 Month
Rising Net Cash Flow and Cash from Operating activity
Relative Outperformance versus Industry over 1 Year
PEG lower than Industry PEG
High Momentum Scores (Technical Scores greater than 50)
Good quarterly growth in the recent results
Relative Outperformance versus Industry over 1 Week
Relative Outperformance versus Industry over 1 Month
Growth in Net Profit with increasing Profit Margin (QoQ)
Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years
Company able to generate Net Cash - Improving Net Cash Flow for last 2 years
Book Value per share Improving for last 2 years
Near 52 Week High
RSI indicating price strength
Top Gainers
Stocks near 52 Week High with Significant Volumes
Stocks Outperforming their Industry Price Change in the Quarter

Promoter decreasing their shareholding
Companies with growing costs YoY for long term projects
PE higher than Industry PE
High PE (PE > 40)
Stocks with Expensive Valuations according to the Trendlyne Valuation Score
Inefficient use of shareholder funds - ROE declining in the last 2 years
Inefficient use of assets to generate profits - ROA declining in the last 2 years
Declining Revenue every quarter for the past 2 quarters
Companies Increasing Debt as per Annual Report
Increasing Trend in Non-Core Income
High promoter stock pledges
Sell Zone: Stocks in the sell zone based on days traded at current PE and P/BV

Broker price or reco upgrades in last month
Brokers upgraded recommendation or target price in the past three months
Mutual Funds Increased Shareholding in Past Month
Broker Upgrades: Stocks where brokers upgraded recommendation or price target in the past one month
FII / FPI or Institutions increasing their shareholding
MFs increased their shareholding last quarter
Broker price or reco upgrades in last month
Mutual Funds Increased Shareholding over the Past Two Months
Mf buying for 2 months

Bullish or Bearish Candlestick Strength - Indices
Average Financial Performers - Stocks with Medium Trendlyne Durability Score versus Benchmarks
Average Bullish Trend - Stocks with Medium Trendlyne Momentum Score versus Benchmarks

Eris Lifesciences Ltd. SWOT Analysis: Strengths, Weakness, Opportunity, and Threats